Clinical trials: Sleeplessness
Insomnia, Insomnia Disorder
DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS
Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can lead to symptoms in the…
- Trial name
- NCT06488027
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- AB Biotek
Sleep Initiation and Maintenance Disorders
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia
The purpose of this study is to determine the safety and efficacy of 4 mg of Ramelteon, once daily (QD), in subjects with chronic insomnia.
- Trial name
- NCT00756002
- Testing
- Ramelteon
- Volunteers
- 259 people
- Sponsor
- Takeda
Schizophrenia, Insomnia
Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients
The primary objective of this study is to evaluate the amelioration of the sleep architecture of patients with schizophrenia and schizophrenia-related insomnia, treated with either 9 mg of extended-release paliperidone ER or…
- Trial name
- NCT00105326
- Testing
- paliperidone ER
- Volunteers
- 5 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Insomnia Disorders
A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
The primary purpose of this study is to evaluate the abuse potential of lemborexant (E2006) in comparison to placebo and 2 controls with known abuse potential (ie, zolpidem and suvorexant) with similar indications (zolpidem and…
- Trial name
- NCT03158025
- Testing
- Zolpidem tablets, Suvorexant tablets, over-encapsulated, Lemborexant tablets
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Primary Insomnia
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia
- Trial name
- NCT00209950
- Testing
- Gaboxadol
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
The purpose of this study is determine whether this drug will improve your insomnia in terms of decreasing your time to fall asleep and allowing you to stay asleep longer.
- Trial name
- NCT00420810
- Testing
- MK0928 / Duration of Treatment : 8 Weeks
- Volunteers
- 138 people
- Sponsor
- H. Lundbeck A/S
Shift Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder
Recovery and Early Sleep Tracking Using the SuperPatch REM Patch
A Phase 1 Feasibility Study of the SuperPatch REM Patch for Post-Night-Shift Sleep Recovery in NHS Doctors
- Conditions
- Shift Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder, Shift Work Sleep Disorders
- Trial name
- REST (NCT07785960)
- Testing
- SuperPatch REM Patch
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- SuperPatch Limited LLC
Chronic Insomnia
Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia
This purpose of this study is to evaluate the safety and effectiveness of Ramelteon, once daily (QD), in elderly participants with chronic insomnia.
- Trial name
- NCT00671255
- Testing
- Ramelteon
- Where
- 115 sites in United States, Canada
- Volunteers
- 829 people
- Sponsor
- Takeda
Depression, Anxiety
Evaluating Neuromodulation Technologies in Early Recovery
The study is an open-label comparative effectiveness clinical trial evaluating the impact of three neuromodulation treatment devices to improve the mental health and sobriety status of recovering substance abuse patients.
- Conditions
- Depression, Anxiety, Insomnia
- Trial name
- NCT01993277
- Testing
- Nexalin Brain Stimulator, Fischer Wallace Stimulator, David Delight Stimulator
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Behavioral Health of the Palm Beaches
Insomnia Disorder
A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder
The purpose of this phase 3 study is to evaluate the efficacy and safety of Daridorexant compared to in participants with insomnia disorder.
- Trial name
- NCT07028697
- Testing
- Daridorexant
- Where
- 17 sites in South Korea
- Volunteers
- 164 people
- Sponsor
- Nxera Pharma Korea Co., Ltd.
Healthy
Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
This study will examine the next-day residual effects of a nighttime dose of gabapentin 250 mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on simulated driving performance in normal…
- Trial name
- NCT01888497
- Testing
- Gabapentin, Diphenhydramine citrate, Triazolam
- Where
- 4 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Insomnia
PK/PD Study of YZJ-1139
Primary Objective： To determine the dose-response relationship of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.
- Trial name
- NCT06685341
- Testing
- YZJ-1139, Zolpidem
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder, Insomnia
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).
- Trial name
- NCT00435279
- Testing
- Eszopiclone, Venlafaxine
- Where
- 69 sites in Austria, Croatia and 8 more
- Volunteers
- 678 people
- Sponsor
- Sumitomo Pharma America, Inc.
Sleep Disturbance
A Study to Evaluate the Effects of the Speed Sleep Supplement on Sleep Quality and Quantity
This study evaluates the effects of the Speed Sleep supplement on sleep quality and quantity in adults aged 18-65 years. Participants will be randomized to receive either the supplement or placebo for 4 weeks, with outcomes…
- Trial name
- NCT07564817
- Testing
- Dietary Supplement: Speed Sleep
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bio Nature Health
Insomnia
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia
The primary objective of the study is to evaluate the safety and tolerability of Neu-P11, following the administration of multiple ascending oral doses (2, 5, 20, 50 mg or matching placebo) given nightly over 2 periods of 5 days…
- Trial name
- NCT01114126
- Testing
- Neu-P11
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Insomnia
A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia
The purpose of this study is to evaluate sleep onset following administration of Transcept zolpidem tartrate sublingual tablet versus placebo in adult insomnia patients.
- Trial name
- NCT00380081
- Testing
- zolpidem tartrate sublingual tablet 3.5mg, zolpidem tartrate sublingual tablet 1.75mg
- Volunteers
- 82 people
- Sponsor
- Transcept Pharmaceuticals
Circadian Dysregulation
Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers
The purpose of this study to determine the degree to which ramelteon, once daily (QD), can reduce the insomnia symptoms associated with rapid, eastward travel across 5 time zones.
- Trial name
- NCT00492011
- Testing
- Ramelteon
- Where
- 4 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Takeda
Insomnia
Effects of Insomnia on Simulated Driving (MK-0000-183-00)
This is a double-blind, parallel design study in elderly primary insomnia patients and demographically matched controls. The objectives if this study are primarily: 1.
- Trial name
- NCT01209728
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Depressive Disorder, Major
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.
- Trial name
- NCT00368030
- Testing
- Eszopiclone
- Where
- 65 sites in United States
- Volunteers
- 545 people
- Sponsor
- Sumitomo Pharma America, Inc.
Insomnia Disorder
Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the…
- Trial name
- NCT06279286
- Testing
- HS-10506
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.